Hogy Medical Co (3593) AI Stock Analysis

• Market Cap: $70.34B
• Dividend Yield: 1.66%
• Average Volume (3M): 155.02K
• Price to Earnings (P/E): 87.5
• Beta (1Y): 0.45
• Revenue Growth: -0.91%
• EPS Growth: -52.71%
• Country: JP
• Employees: 1,408
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 33.99
• Shares Outstanding: 22,535,463
• 10 Day Avg. Volume: 354,810
• 30 Day Avg. Volume: 155,020
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 2.00
• Enterprise Value/Gross Profit: 6.20
• Enterprise Value/Ebitda: 8.09
• 1Y Price Target: $5,102.92
• Price Target Upside: 1.25% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 69 Neutral
• Price Target: ¥5,103.00 ▲(1.25% Upside)

Hogy Medical Co's overall stock score is driven primarily by its strong financial stability and consistent cash flow generation. However, technical analysis suggests potential overbought conditions, and the high P/E ratio indicates a possible overvaluation, which could limit upside potential.

Hogy Medical Co Business Overview & Revenue Model

Company Description

Hogy Medical Co.,Ltd., together with its subsidiaries, manufactures and sells medical supplies to healthcare facilities in Japan. It offers kit products for surgery applications; all-in-one kits for pre/mid/post-surgery; non-woven products, including gowns, personal protective equipment and wearables, drapes, packaged products, instrument table covers, and wraps; and Tigalyer, a multi-layer fabric. The company also provides sterilization products, such as hybrid Mekkin bags, hybrid Mekkin bags ID layered type, and autoclave forceps stand caps; Mekkin cards, which are detection cards used to judge the sterilization process when sterilizing in an autoclave; ethylene oxide gas cards that are detection cards used to judge the sterilization process when sterilizing using ethylene oxide gas; and indicator tapes for autoclave sterilization. In addition, it offers ME equipment operation management system; narcotics/poisons box, an automatic drug reading management system using radio frequency identification; and Securea, a polyurethane sponge for endoscopic surgery. The company was formerly known as Hogy Co., Ltd. and changed its name to Hogy Medical Co.,Ltd. in 1987. Hogy Medical Co.,Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Hogy Medical Co generates revenue through the sale of its medical and surgical products. The company's primary revenue streams include the production and distribution of surgical gloves, drapes, and procedure kits, which are essential components in surgical and medical procedures. Hogy Medical Co's revenue is driven by its ability to maintain strong relationships with hospitals and healthcare providers, ensuring a steady demand for its high-quality and reliable products. Additionally, the company may benefit from strategic partnerships and collaborations that enhance its market presence and access to new technologies, although specific details about such partnerships are not readily available.

Hogy Medical Co Financial Statement Overview

Summary

Hogy Medical Co demonstrates financial stability with a strong balance sheet and consistent cash flow generation. Despite some declines in profitability margins, the company maintains solid revenue and gross margin performance. Low leverage and a high equity ratio enhance its financial resilience.

Income Statement

Hogy Medical Co shows solid revenue stability with a slight increase in revenue over the years. The Gross Profit Margin is consistently strong, indicating effective cost management. However, there's a notable decline in Net Profit Margin and EBIT Margin in the latest year compared to prior periods, suggesting increased operational costs or lower pricing power. The EBITDA Margin remains robust, highlighting strong earnings before accounting for interest, taxes, depreciation, and amortization.

Balance Sheet

The company maintains a healthy balance sheet with a very low Debt-to-Equity Ratio, indicating low financial leverage. The Return on Equity has seen some fluctuation but remains positive, reflecting efficient use of equity capital. The Equity Ratio is high, signifying strong financing through equity and low reliance on debt, which provides financial stability.

Cash Flow

Hogy Medical Co exhibits strong cash flow with consistent Free Cash Flow generation and growth in Operating Cash Flow. The Free Cash Flow to Net Income Ratio indicates solid cash generation relative to net income, despite some variability in Free Cash Flow growth over the years. The Operating Cash Flow to Net Income Ratio showcases the company's ability to convert net income into cash effectively.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	39.14B	39.10B	38.98B	36.78B	36.50B
Gross Profit	12.62B	12.49B	15.74B	15.42B	15.33B
EBITDA	8.75B	10.71B	10.25B	10.25B	10.18B
Net Income	1.52B	2.80B	4.32B	4.37B	4.96B
Balance Sheet
Total Assets	97.89B	100.04B	102.18B	98.97B	105.64B
Cash, Cash Equivalents and Short-Term Investments	22.00B	19.42B	18.86B	14.36B	20.55B
Total Debt	13.67B	5.82B	8.89B	10.00B	330.00M
Total Liabilities	23.56B	13.92B	18.50B	18.97B	9.69B
Stockholders Equity	74.32B	86.11B	83.61B	79.96B	95.88B
Cash Flow
Free Cash Flow	6.53B	4.32B	7.78B	5.30B	-686.00M
Operating Cash Flow	11.76B	7.12B	9.18B	8.50B	6.85B
Investing Cash Flow	-4.12B	-3.26B	-1.95B	-3.81B	-6.95B
Financing Cash Flow	-5.46B	-3.89B	-3.14B	-11.05B	-2.50B

Hogy Medical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5040.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3593, the sentiment is Positive. The current price of 5040 is above the 20-day moving average (MA) of 4423.25, above the 50-day MA of 4096.88, and above the 200-day MA of 4436.52, indicating a bullish trend. The MACD of 291.45 indicates Negative momentum. The RSI at 82.64 is Negative, neither overbought nor oversold. The STOCH value of 66.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3593.

Hogy Medical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3593	69 Neutral	$70.34B	87.50	1.63%	1.66%	-0.91%	-52.71%
Sector *	47 Neutral	C$212.69M	-2.68	-24.76%	3.10%	19.76%	0.48%
6SN	―	€965.49M	30.41	4.39%	―	―	―
PBHDF	―	$972.94M	17.99	6.38%	3.09%	―	―
7730	72 Outperform	¥129.36B	23.70		2.99%	5.82%	-20.09%
3154	63 Neutral	¥19.10B	13.87		2.33%	11.12%	20.54%
7702	56 Neutral	¥10.70B	124.68		3.82%	3.36%	-310.49%

Hogy Medical Co Corporate Events

Hogy Medical Co. Clarifies Privatization Speculation

Hogy Medical Co., Ltd. addressed recent media reports suggesting its potential privatization, clarifying that while it is considering various options to enhance corporate value, no official decision has been made. This announcement indicates the company’s strategic exploration to potentially reposition itself in the market, though stakeholders should note that no concrete plans have been finalized.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Co. Reports Decline in Q1 2025 but Projects Growth

Hogy Medical Co., Ltd. reported a decline in its financial performance for the three months ended June 30, 2025, with net sales and profits decreasing compared to the previous year. Despite the downturn, the company plans to increase its annual dividends per share and forecasts a positive growth in net sales and profits for the full fiscal year ending March 31, 2026, indicating a strategic focus on long-term growth and shareholder value.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Co. Announces Shareholder Meeting Outcomes

Hogy Medical Co., Ltd. announced the results of its 64th Annual General Meeting of Shareholders, where the proposal for the election of directors was approved. Although one director candidate nominated by shareholders was elected, the company noted that this individual does not meet its criteria for independence. The newly elected director is expected to strengthen management oversight, contributing from a unique perspective compared to the current independent directors.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Announces Leadership Restructuring

Hogy Medical Co., Ltd. announced significant changes to its Board of Directors and executive officers, effective June 20, 2025, and July 1, 2025, respectively. These changes are expected to enhance the company’s leadership structure, potentially impacting its strategic direction and operational efficiency, which could have implications for stakeholders and the company’s market positioning.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical’s Board Opposes Shareholder Proposal on Director Elections

Hogy Medical Co., Ltd.’s Board of Directors has decided to oppose a shareholder proposal from Nippon Active Value Fund plc regarding the election of three directors at the upcoming Annual General Meeting. The Board believes that its current composition, which includes a Nomination Committee to ensure independence and accountability, is optimal for implementing its medium-term management plan aimed at sustainable growth and enhanced corporate governance.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Co. Announces Leadership Changes to Strengthen Management

Hogy Medical Co., Ltd. announced a significant change in its leadership structure, with Taisuke Fujita being appointed as the new Representative Director and Vice President, effective June 20, 2025. This strategic move aims to strengthen the company’s management framework, potentially impacting its operational efficiency and market positioning. Additionally, the company will see the resignation of two outside directors, Kiyoshi Uesugi and Yuta Kinose, on the same date.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.